Table 1.
Summary of Patients–presenting Features.
| Patient | Age (yr) | Initial PSA (ng/mL) | Gleason score | Clinical stage | Sites of metastasis | Time from diagnosis to surgery | Pre-operative ADT | Local symptoms | Cytoreductive surgery |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 77 | 7.8 | 4+5 | T2b | 7th rib | 4 wk | – | – | RARP |
| 2 | 65 | 30.0 | 4+5 | T2b | Right inferior pubic ramus | 11 mo | LHRH agonist | Obstructive voiding symptoms | RARP |
| 3 | 69 | 27.0 | 5+4 | T3b | L3 vertebra | 4 wk | – | – | RARP |
| 4 | 49 | 62.0 | 4+4 | T2b | T11 vertebra | 5 y | LHRH agonist | – | RARP |
| 5 | 68 | 81.0 | 4+3 | T4 | 4th rib, T7 vertebral body | 9 y | LHRH agonist + bicalutamide | Haematuria, bladder outlet & ureteric obstruction | Pelvic exenteration |
| 6 | 55 | 45.0 | 4+4 | Not known | Symphysis pubis, right inferior pubic ramus, & left internal iliac node | 5 mo | LHRH agonist | – | RARP |
ADT, androgen-deprivation therapy; LHRH, luteinizing hormone-releasing hormone; PSA, prostate-specific antigen; RARP, robot-assisted radical prostatectomy.